The WACC of Enlie Pharmaceutical JSC (BCP.VN) is 11.0%.
| Range | Selected | |
| Cost of equity | 8.80% - 10.80% | 9.80% |
| Tax rate | 0.10% - 1.00% | 0.55% |
| Cost of debt | 11.90% - 14.50% | 13.20% |
| WACC | 9.9% - 12.1% | 11.0% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 9.5% | 10.5% |
| Adjusted beta | 0.64 | 0.67 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.80% | 10.80% |
| Tax rate | 0.10% | 1.00% |
| Debt/Equity ratio | 0.58 | 0.58 |
| Cost of debt | 11.90% | 14.50% |
| After-tax WACC | 9.9% | 12.1% |
| Selected WACC | 11.0% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for BCP.VN:
cost_of_equity (9.80%) = risk_free_rate (2.95%) + equity_risk_premium (10.00%) * adjusted_beta (0.64) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.